| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | AMG-706 | GDSC1000 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | 0.028 | 0.6 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.6 |
| mRNA | nakiterpiosin | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |